Skip to main content
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2005 May;90(5):494–499. doi: 10.1136/adc.2003.036590

Bisphosphonate treatment of bone disease

N Shaw 1, N Bishop 1
PMCID: PMC1720410  PMID: 15851432

Full Text

The Full Text of this article is available as a PDF (86.0 KB).

Figure 1.

Figure 1

 Structure of pyrophosphate and bisphosphonate.

Figure 2.

Figure 2

 Cascade of events triggered by administration of a bisphosphonate.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allgrove J. Biphosphonates. Arch Dis Child. 1997 Jan;76(1):73–75. doi: 10.1136/adc.76.1.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aström E., Söderhäll S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002 May;86(5):356–364. doi: 10.1136/adc.86.5.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Attard T. M., Dhawan A., Kaufman S. S., Collier D. S., Langnas A. N. Use of disodium pamidronate in children with hypercalcemia awaiting liver transplantation. Pediatr Transplant. 1998 May;2(2):157–159. [PubMed] [Google Scholar]
  4. Batch J. A., Couper J. J., Rodda C., Cowell C. T., Zacharin M. Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health. 2003 Mar;39(2):88–92. doi: 10.1046/j.1440-1754.2003.00083.x. [DOI] [PubMed] [Google Scholar]
  5. Benford H. L., McGowan N. W., Helfrich M. H., Nuttall M. E., Rogers M. J. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001 May;28(5):465–473. doi: 10.1016/s8756-3282(01)00412-4. [DOI] [PubMed] [Google Scholar]
  6. Bianchi M. L., Cimaz R., Bardare M., Zulian F., Lepore L., Boncompagni A., Galbiati E., Corona F., Luisetto G., Giuntini D. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000 Sep;43(9):1960–1966. doi: 10.1002/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  7. Bielinski Basia K., Darbyshire Phil J., Mathers Lynne, Crabtree Nicola J., Kirk Jeremy M. W., Stirling Heather F., Shaw Nick J. Impact of disordered puberty on bone density in beta-thalassaemia major. Br J Haematol. 2003 Jan;120(2):353–358. doi: 10.1046/j.1365-2141.2003.04066.x. [DOI] [PubMed] [Google Scholar]
  8. Brumsen C., Hamdy N. A., Papapoulos S. E. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997 Jul;76(4):266–283. doi: 10.1097/00005792-199707000-00005. [DOI] [PubMed] [Google Scholar]
  9. Chapurlat R. D., Delmas P. D., Liens D., Meunier P. J. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res. 1997 Oct;12(10):1746–1752. doi: 10.1359/jbmr.1997.12.10.1746. [DOI] [PubMed] [Google Scholar]
  10. Cundy Tim, Wheadon Lisa, King Alan. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy. J Bone Miner Res. 2004 Jan 19;19(5):703–711. doi: 10.1359/JBMR.040127. [DOI] [PubMed] [Google Scholar]
  11. Fewtrell M. S., British Paediatric & Adolescent Bone Group Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls. Arch Dis Child. 2003 Sep;88(9):795–798. doi: 10.1136/adc.88.9.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Glorieux F. H., Bishop N. J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998 Oct 1;339(14):947–952. doi: 10.1056/NEJM199810013391402. [DOI] [PubMed] [Google Scholar]
  13. Go T. Low-dose oral etidronate therapy for immobilization hypercalcaemia associated with Guillain-Barré syndrome. Acta Paediatr. 2001 Oct;90(10):1202–1204. doi: 10.1080/080352501317061666. [DOI] [PubMed] [Google Scholar]
  14. Henderson Richard C., Lark Robert K., Kecskemethy Heidi H., Miller Freeman, Harcke H. Theodore, Bachrach Steven J. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002 Nov;141(5):644–651. doi: 10.1067/mpd.2002.128207. [DOI] [PubMed] [Google Scholar]
  15. Hosking David, Adami Silvano, Felsenberg Dieter, Andia Jorge Cannata, Välimäki Matti, Benhamou Laurent, Reginster Jean-Yves, Yacik Carol, Rybak-Feglin Andrea, Petruschke Richard A. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin. 2003;19(5):383–394. doi: 10.1185/030079903125002009. [DOI] [PubMed] [Google Scholar]
  16. Kanumakala S., Boneh A., Zacharin M. Pamidronate treatment improves bone mineral density in children with Menkes disease. J Inherit Metab Dis. 2002 Sep;25(5):391–398. doi: 10.1023/a:1020103901969. [DOI] [PubMed] [Google Scholar]
  17. Kedlaya D., Brandstater M. E., Lee J. K. Immobilization hypercalcemia in incomplete paraplegia: successful treatment with pamidronate. Arch Phys Med Rehabil. 1998 Feb;79(2):222–225. doi: 10.1016/s0003-9993(98)90304-5. [DOI] [PubMed] [Google Scholar]
  18. Lteif A. N., Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics. 1998 Oct;102(4 Pt 1):990–993. doi: 10.1542/peds.102.4.990. [DOI] [PubMed] [Google Scholar]
  19. Luckman S. P., Hughes D. E., Coxon F. P., Graham R., Russell G., Rogers M. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998 Apr;13(4):581–589. doi: 10.1359/jbmr.1998.13.4.581. [DOI] [PubMed] [Google Scholar]
  20. Montpetit Kathleen, Plotkin Horacio, Rauch Frank, Bilodeau Nathalie, Cloutier Suzanne, Rabzel Mary, Glorieux Francis H. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics. 2003 May;111(5 Pt 1):e601–e603. doi: 10.1542/peds.111.5.e601. [DOI] [PubMed] [Google Scholar]
  21. Mukamel M., Horev G., Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001 May;138(5):763–766. doi: 10.1067/mpd.2001.112473. [DOI] [PubMed] [Google Scholar]
  22. Munns Craig F., Rauch Frank, Mier Richard J., Glorieux Francis H. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone. 2004 Jul;35(1):231–234. doi: 10.1016/j.bone.2004.03.008. [DOI] [PubMed] [Google Scholar]
  23. Noguera A., Ros J. B., Pavía C., Alcover E., Valls C., Villaronga M., González E. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab. 2003 Apr-May;16(4):529–536. doi: 10.1515/jpem.2003.16.4.529. [DOI] [PubMed] [Google Scholar]
  24. Peter Rajesh, Mishra Vinita, Fraser William D. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ. 2004 Feb 7;328(7435):335–336. doi: 10.1136/bmj.328.7435.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Plotkin H., Rauch F., Bishop N. J., Montpetit K., Ruck-Gibis J., Travers R., Glorieux F. H. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000 May;85(5):1846–1850. doi: 10.1210/jcem.85.5.6584. [DOI] [PubMed] [Google Scholar]
  26. Plotkin Horacio, Rauch Frank, Zeitlin Leonid, Munns Craig, Travers Rose, Glorieux Francis H. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. 2003 Oct;88(10):4569–4575. doi: 10.1210/jc.2003-030050. [DOI] [PubMed] [Google Scholar]
  27. Rauch Frank, Glorieux Francis H. Osteogenesis imperfecta. Lancet. 2004 Apr 24;363(9418):1377–1385. doi: 10.1016/S0140-6736(04)16051-0. [DOI] [PubMed] [Google Scholar]
  28. Rauch Frank, Plotkin Horacio, Travers Rose, Zeitlin Leonid, Glorieux Francis H. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab. 2003 Mar;88(3):986–992. doi: 10.1210/jc.2002-021371. [DOI] [PubMed] [Google Scholar]
  29. Rauch Frank, Plotkin Horacio, Zeitlin Leonid, Glorieux Francis H. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res. 2003 Apr;18(4):610–614. doi: 10.1359/jbmr.2003.18.4.610. [DOI] [PubMed] [Google Scholar]
  30. Rauch Frank, Travers Rose, Munns Craig, Glorieux Francis H. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res. 2004 Jul 1;19(7):1191–1193. doi: 10.1359/JBMR.040303. [DOI] [PubMed] [Google Scholar]
  31. Rauch Frank, Travers Rose, Plotkin Horacio, Glorieux Francis H. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002 Nov;110(9):1293–1299. doi: 10.1172/JCI15952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Reid Ian R., Brown Jacques P., Burckhardt Peter, Horowitz Zebulun, Richardson Peter, Trechsel Ulrich, Widmer Albert, Devogelaer Jean-Pierre, Kaufman Jean-Marc, Jaeger Philippe. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002 Feb 28;346(9):653–661. doi: 10.1056/NEJMoa011807. [DOI] [PubMed] [Google Scholar]
  33. Rice A. M., Rivkees S. A. Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn. J Pediatr. 1999 Mar;134(3):349–351. doi: 10.1016/s0022-3476(99)70462-2. [DOI] [PubMed] [Google Scholar]
  34. Rogers M. J., Ji X., Russell R. G., Blackburn G. M., Williamson M. P., Bayless A. V., Ebetino F. H., Watts D. J. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J. 1994 Oct 1;303(Pt 1):303–311. doi: 10.1042/bj3030303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rosen Clifford J., Brown Sue. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med. 2003 Apr 10;348(15):1503–1504. doi: 10.1056/NEJM200304103481521. [DOI] [PubMed] [Google Scholar]
  36. Sakkers Ralph, Kok Dieke, Engelbert Raoul, van Dongen Alice, Jansen Maarten, Pruijs Hans, Verbout Ab, Schweitzer Dave, Uiterwaal Cuno. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004 May 1;363(9419):1427–1431. doi: 10.1016/S0140-6736(04)16101-1. [DOI] [PubMed] [Google Scholar]
  37. Shoemaker L. R. Expanding role of bisphosphonate therapy in children. J Pediatr. 1999 Mar;134(3):264–267. doi: 10.1016/s0022-3476(99)70447-6. [DOI] [PubMed] [Google Scholar]
  38. Steelman Joel, Zeitler Philip. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr. 2003 Apr;142(4):417–423. doi: 10.1067/mpd.2003.137. [DOI] [PubMed] [Google Scholar]
  39. Whyte Michael P., Wenkert Deborah, Clements Karen L., McAlister William H., Mumm Steven. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003 Jul 31;349(5):457–463. doi: 10.1056/NEJMoa023110. [DOI] [PubMed] [Google Scholar]
  40. Young G., Shende A. Use of pamidronate in the management of acute cancer-related hypercalcemia in children. Med Pediatr Oncol. 1998 Feb;30(2):117–121. doi: 10.1002/(sici)1096-911x(199802)30:2<117::aid-mpo9>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  41. Zacharin M., Cundy T. Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. J Pediatr. 2000 Sep;137(3):410–415. doi: 10.1067/mpd.2000.107838. [DOI] [PubMed] [Google Scholar]
  42. Zacharin Margaret, Bateman John. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab. 2002 Feb;15(2):163–174. doi: 10.1515/jpem.2002.15.2.163. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES